A comparison of adherence and persistence levels among schizophrenia patients treated with atypical antipsychotics

Zhu, Bi; Gibson, P. Joseph; Ascher-Svanum, Haya; Opolka, Jayme L.

doi:10.1016/s0920-9964(03)80363-8

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recognizing the importance of treatment persistence in controlling symptoms of schizophrenia, a number of studies have compared levels of treatment persistence across different antipsychotic agents (Cramer and Rosenheck 1999; Dixon et al 1999; Vanelli et al 2001; Dolder et al 2002; Zhu et al 2003; Ren et al 2006). However, the results of these studies tend to be mixed.…”

Section: Introductionmentioning

confidence: 99%

An alternative approach to measuring treatment persistence with antipsychotic agents among patients with schizophrenia in the Veterans Health Administration

Ren¹,

Qian²,

Kazis³

2007

Neuropsychiatric Disease and Treatment

View full text Add to dashboard Cite

Prior studies have demonstrated the importance of treatment persistence with antipsychotic agents in sustaining control of schizophrenic symptoms. However, the conventional approach in measuring treatment persistence tended to use only the fi rst prescription episode even though some patients received multiple prescriptions (or multiple treatment episodes) of the same medication within one year following the initiation of the index drug. In this study, we used data from the Veterans Health Administration in the United States to assess the extent to which patients received multiple prescriptions. The study found that about a quarter of the patients had two or more treatment episodes and that levels of treatment persistence tended to vary across treatment episodes. Based on these results, we offered an alternative approach in which we calculated treatment persistence with typical and atypical antipsychotic agents separately for patients with one, two, or three treatment episodes. Considering that patients with different number of treatment episodes might differ in disease profi les, this treatment episode-specifi c approach offered a fair comparison of the levels of treatment persistence across patients with different number of treatment episodes. Future research needs to extend the analyses beyond two antipsychotic classes to individual antipsychotic agents. A more comprehensive assessment using appropriate analytic methods should help physicians make prescription choices that will ultimately improve the care of patients with schizophrenia.

show abstract

Section: Introductionmentioning

confidence: 99%

An alternative approach to measuring treatment persistence with antipsychotic agents among patients with schizophrenia in the Veterans Health Administration

Ren¹,

Qian²,

Kazis³

2007

Neuropsychiatric Disease and Treatment

View full text Add to dashboard Cite

show abstract

“…Due to different side effects associated with different classes of antipsychotic agents (18, 19), prior studies have compared treatment persistence between typical (or first generation) and atypical (or second generation) antipsychotic agents as well as across different atypical antipsychotic agents (20–22). These studies indicated that treatment persistence tended to be better with atypical antipsychotic agents than with typical antipsychotic agents (21, 22), and that the patients treated with olanzapine were significantly more likely to stay on their medication for a longer duration than patients who received risperidone or quetiapine (20, 23, 24).…”

Section: Introductionmentioning

confidence: 99%

Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents

et al. 2006

View full text Add to dashboard Cite

Compared with risperidone, olanzapine seems to be better tolerated by patients as indicated by better treatment persistence. As such, initiation of olanzapine may increase the likelihood of sustaining control of symptoms of schizophrenia. Future research needs to provide a more comprehensive assessment of treatment persistence by considering other antipsychotic agents in the study and developing models to assess treatment persistence and switching as two interdependent competing risks.

show abstract

Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia

Ren

Kazis

Lee

et al. 2005

Schizophrenia Research

View full text Add to dashboard Cite

A comparison of adherence and persistence levels among schizophrenia patients treated with atypical antipsychotics

Cited by 3 publications

References 0 publications

An alternative approach to measuring treatment persistence with antipsychotic agents among patients with schizophrenia in the Veterans Health Administration

An alternative approach to measuring treatment persistence with antipsychotic agents among patients with schizophrenia in the Veterans Health Administration

Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents

Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia

Contact Info

Product

Resources

About